Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status

Lu F, Ahmed AA, Zhang S, Raman VK, Patel SS, Vargas JD, Fonarow GC, Heidenreich PA, Cleland JGF, Anker SD, Böhm M, Metra M, Zile[...]

Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes

Andrade-Bucknor S, Barforoshi S, Le DE, Lyubarova R, Chung J. Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis[...]

Transthyretin Cardiac Amyloidosis in an Older Athlete

O'Brien D, Reiss RA. Transthyretin Cardiac Amyloidosis in an Older Athlete. Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. PMID: 42534173; PMCID: PMC13419844.